124 related articles for article (PubMed ID: 35414511)
1. Novel Biomarker Panels Discriminating between Pancreatic Ductal Adenocarcinoma and Extrahepatic Bile Duct Carcinoma.
Noh BJ; Choi GM; Jang HJ; Ma CH; Oh HS; Kim M; Eom DW
Ann Clin Lab Sci; 2022 Mar; 52(2):323-331. PubMed ID: 35414511
[TBL] [Abstract][Full Text] [Related]
2. Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma.
Zhu J; Wu J; Pei X; Tan Z; Shi J; Lubman DM
PLoS One; 2017; 12(4):e0175039. PubMed ID: 28369074
[TBL] [Abstract][Full Text] [Related]
3. Annexin A10 optimally differentiates between intrahepatic cholangiocarcinoma and hepatic metastases of pancreatic ductal adenocarcinoma: a comparative study of immunohistochemical markers and panels.
Kälsch J; Padden J; Bertram S; Pott LL; Reis H; Westerwick D; Schaefer CM; Sowa JP; Möllmann D; Fingas C; Dechȇne A; Sitek B; Eisenacher M; Canbay A; Ahrens M; Baba HA
Virchows Arch; 2017 May; 470(5):537-543. PubMed ID: 28357490
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) Discovered by Proteomic Analysis of Microdissected Cells.
Padden J; Ahrens M; Kälsch J; Bertram S; Megger DA; Bracht T; Eisenacher M; Kocabayoglu P; Meyer HE; Sipos B; Baba HA; Sitek B
Mol Cell Proteomics; 2016 Mar; 15(3):1072-82. PubMed ID: 26644413
[TBL] [Abstract][Full Text] [Related]
5. High Annexin A10 expression is correlated with poor prognosis in pancreatic ductal adenocarcinoma.
Ishikawa A; Kuraoka K; Zaitsu J; Saito A; Yamaguchi A; Kuwai T; Sudo T; Hadano N; Tashiro H; Taniyama K; Yasuif W
Histol Histopathol; 2022 Mar; 37(3):243-250. PubMed ID: 34821375
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.
Kruger D; Yako YY; Devar J; Lahoud N; Smith M
PLoS One; 2019; 14(8):e0221169. PubMed ID: 31415645
[TBL] [Abstract][Full Text] [Related]
7. Novel biomarkers distinguishing pancreatic head Cancer from distal cholangiocarcinoma based on proteomic analysis.
Takenami T; Maeda S; Karasawa H; Suzuki T; Furukawa T; Morikawa T; Takadate T; Hayashi H; Nakagawa K; Motoi F; Naitoh T; Unno M
BMC Cancer; 2019 Apr; 19(1):318. PubMed ID: 30953499
[TBL] [Abstract][Full Text] [Related]
8. Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and Bile Duct.
Singhi AD; Wood LD; Parks E; Torbenson MS; Felsenstein M; Hruban RH; Nikiforova MN; Wald AI; Kaya C; Nikiforov YE; Favazza L; He J; McGrath K; Fasanella KE; Brand RE; Lennon AM; Furlan A; Dasyam AK; Zureikat AH; Zeh HJ; Lee K; Bartlett DL; Slivka A
Gastroenterology; 2020 Feb; 158(3):573-582.e2. PubMed ID: 31678302
[TBL] [Abstract][Full Text] [Related]
9. FOXF1 as an Immunohistochemical Marker of Hilar Cholangiocarcinoma or Metastatic Pancreatic Ductal Adenocarcinoma. Single Institution Experience.
Hrudka J; Prouzová Z; Mydlíková K; Jedličková K; Holešta M; Whitley A; Havlůj L
Pathol Oncol Res; 2021; 27():1609756. PubMed ID: 34257615
[TBL] [Abstract][Full Text] [Related]
10. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile.
Cote GA; Gore AJ; McElyea SD; Heathers LE; Xu H; Sherman S; Korc M
Am J Gastroenterol; 2014 Dec; 109(12):1942-52. PubMed ID: 25350767
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma.
Lok T; Chen L; Lin F; Wang HL
Hum Pathol; 2014 Feb; 45(2):394-400. PubMed ID: 24439226
[TBL] [Abstract][Full Text] [Related]
12. Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity.
Schmuck RB; de Carvalho-Fischer CV; Neumann C; Pratschke J; Bahra M
Cancer Med; 2016 Jan; 5(1):88-99. PubMed ID: 26645826
[TBL] [Abstract][Full Text] [Related]
13. Adenocarcinoma with pyloric gland phenotype of the extrahepatic bile ducts: a previously unrecognized and distinctive morphologic variant of extrahepatic bile duct carcinoma.
Albores-Saavedra J; Chablé-Montero F; Méndez-Sánchez N; Mercado MÁ; Vilatoba-Chapa M; Henson DE
Hum Pathol; 2012 Dec; 43(12):2292-8. PubMed ID: 22795356
[TBL] [Abstract][Full Text] [Related]
14. Strong Annexin A10 Expression Supports a Pancreatic Primary and Combined Annexin A10, Claudin 18, and SOX2 Expression Supports an Esophagogastric Origin in Carcinomas of Unknown Primary.
Isidro RA; Abukhiran I; Dunseth CD; Gosse MD; Humble RM; Pelletier DJ; Varshney N; Bellizzi AM; Hornick JL
Am J Surg Pathol; 2023 Apr; 47(4):440-452. PubMed ID: 36730833
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma.
Sopha SC; Gopal P; Merchant NB; Revetta FL; Gold DV; Washington K; Shi C
Int J Clin Exp Pathol; 2013; 6(11):2476-86. PubMed ID: 24228110
[TBL] [Abstract][Full Text] [Related]
16. Expression of GalNAc-T3 and its relationships with clinicopathological factors in 61 extrahepatic bile duct carcinomas analyzed using stepwise sections - special reference to its association with lymph node metastases-.
Inoue T; Eguchi T; Oda Y; Nishiyama K; Fujii K; Izumi H; Kohno K; Yamaguchi K; Tanaka M; Tsuneyoshi M
Mod Pathol; 2007 Feb; 20(2):267-76. PubMed ID: 17361208
[TBL] [Abstract][Full Text] [Related]
17. The cellular composition of osteoclastlike giant cell-containing tumors of the pancreatobiliary tree.
Dhall D; Klimstra DS
Am J Surg Pathol; 2008 Feb; 32(2):335-7; author response 337. PubMed ID: 18223338
[No Abstract] [Full Text] [Related]
18. Clinicopathological significance of olfactomedin-4 in extrahepatic bile duct carcinoma.
Jun SY; An S; Huh T; Chung JY; Hong SM
Pathol Res Pract; 2020 May; 216(5):152940. PubMed ID: 32276789
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic ductal adenocarcinoma with a predominant large duct pattern has better recurrence-free survival than conventional pancreatic ductal adenocarcinoma: a comprehensive histopathological, immunohistochemical, and mutational study.
Kim SJ; Choi SJ; Yang J; Kim D; Kim DW; Byun JH; Hong SM
Hum Pathol; 2022 Sep; 127():39-49. PubMed ID: 35667635
[TBL] [Abstract][Full Text] [Related]
20. Critical role of type IV collagens in the growth of bile duct carcinoma. In vivo and in vitro studies.
Chen Y; Satoh T; Sasatomi E; Miyazaki K; Tokunaga O
Pathol Res Pract; 2001; 197(9):585-96. PubMed ID: 11569922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
